Morrison & Foerster and the Berkeley Center for Law & Technology (BCLT) have teamed up to present a recurring podcast addressing recent Federal Circuit decisions.
In this episode, Brian Matsui, a partner in Morrison & Foerster's Appellate + Supreme Court practice and Allison Schmitt, BCLT's Life Sciences project director discuss:
- When do post-marketing tests required by the U.S. Food and Drug Administration (FDA) that lead to the claimed combination not demonstrate obviousness?
- The interplay between reasonable expectation of success and disclosed ranges in prior art.
Listen now on Spotify, Apple, or Google.
Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Morrison & Foerster LLP. All rights reserved
